Scaling factors for thein vitro-in vivoextrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearance-Reference-Cited by-同舟云学术

Scaling factors for thein vitro-in vivoextrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearance

Published:2016-03-14 Issue:6 Volume:81 Page:1153-1164
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Knights Kathleen M.¹,Spencer Shane M.¹,Fallon John K.²^ORCID,Chau Nuy¹,Smith Philip C.²,Miners John O.¹

Affiliation:

1. Department of Clinical Pharmacology and Flinders Centre for Innovation in Cancer, School of Medicine; Flinders University; Adelaide South Australia Australia 5001

2. Division of Molecular Pharmaceutics, Eshelman School of Pharmacy; University of North Carolina at Chapel Hill; Chapel Hill North Carolina 27599 USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.12889/fullpdf

Reference58 articles.

1. Human renal cortical and medullary UDP-glucuronosyltransferases (UGTs): immunohistochemical localization of UGT2B7 and UGT1A enzymes and kinetic characterization of S-naproxen glucuronidation;Gaganis;J Pharmacol Exp Ther,2007

2. S-naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen;Bowalgaha;Br J Clin Pharmacol,2005

3. Characteristics of renal UDP-glucuronosyltransferase;Rush;Life Sci,1984

4. Glucuronidation and sulfation in rabbit kidney;Hjelle;J Pharmacol Exp Ther,1986

5. Glucuronidation of morphine in human kidney microsomes;Yue;Pharmacol Toxicol,1988

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Relative Activity versus Relative Expression Factors (RAF versus REF) in Predicting Glucuronidation Mediated Drug Clearance Using Recombinant UGTs;Pharmaceutical Research;2024-08

2. After 50 Years of Hepatic Clearance Models, Where Should We Go from Here? Improvements and Implications for Physiologically Based Pharmacokinetic Modeling;Drug Metabolism and Disposition;2024-05-08

3. Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance;Pharmacology & Therapeutics;2023-08

4. Achieving a Deeper Understanding of Drug Metabolism and Responses Using Single-Cell Technologies;Drug Metabolism and Disposition;2023-01-10

5. Examining Physiologically Based Pharmacokinetic Model Assumptions for Cross-Tissue Similarity of Activity per Unit of Enzyme: The Case Example of Uridine 5′-Diphosphate Glucuronosyltransferase;Drug Metabolism and Disposition;2022-05-30